AstraZeneca announces multibillion dollar investments in China as Big Pharma is increasingly looking east for innovation.
6don MSN
AstraZeneca strikes deal for up to $18.5 billion to license weight-loss drugs from China's CSPC
By Andrew Silver SHANGHAI, Jan 30 (Reuters) - AstraZeneca will license experimental drugs for obesity and weight-related ...
Feb 3 () - AstraZeneca said on Tuesday the U. health regulator has rejected its application for a self-injectable version ...
Feb 3 (Reuters) - AstraZeneca said on Tuesday that the U.S. health regulator had rejected its application for an ...
AstraZeneca (AZN) has struck an obesity drug deal with Chinese company CSPC Pharmaceutical Group (CHJTF) worth up to $18.5B ...
The agreement, to gain rights to a portfolio of early-stage experimental obesity and diabetes drugs is the largest of its ...
The agency’s program will be open to pharmaceutical facilities that align with “national priorities.” Elsewhere, a ...
British pharmaceutical group AstraZeneca said Thursday that it would invest $15 billion in China through 2030 to expand its ...
The company is working with the U.S. regulator to move forward with an updated application, adding a decision is expected in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results